Sunshine finally: Ranbaxy gets FDA ok for Diovan generic
This article was originally published in Scrip
Executive Summary
Finally, the sun seems to be shining on Ranbaxy. Ending prolonged speculation on the fate of its generic version of Novartis's blockbuster blood pressure treatment Diovan (valsartan) amid mounting pressure from competitors, Ranbaxy said it had received US FDA approval for the product on an "exclusive basis."